Omrix gets US OK for second-generation fibrin sealant, looks to new markets:
This article was originally published in Clinica
Executive Summary
Omrix Biopharmaceuticals has gained US clearance to sell its second-generation fibrin sealant to control bleeding during liver surgery, and has also announced plans to broaden its target market. The new sealant, Evicel, differs from its previous fibrin sealant, Crosseal, in that it does not contain a stabiliser, and will, therefore, not have the neurosurgical contraindication presented by the earlier product. As for new applications, the New York company has submitted an application to the FDA to expand Evicel's indication to include vascular surgery. It is also conducting a clinical study of the sealant in kidney surgery. An indication for general haemostasis requires the completion of at least three pivotal clinical studies, of which the firm has now completed two - liver and peripheral vascular surgery. Omrix' haemostasis products are distributed by Johnson & Johnson firm Ethicon.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.